Exact Sciences Co. (NASDAQ:EXAS) Stock Holdings Lifted by AQR Capital Management LLC

AQR Capital Management LLC increased its stake in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 132.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 592,385 shares of the medical research company's stock after purchasing an additional 337,727 shares during the period. AQR Capital Management LLC owned approximately 0.32% of Exact Sciences worth $33,286,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of EXAS. Lido Advisors LLC lifted its position in shares of Exact Sciences by 351.5% in the fourth quarter. Lido Advisors LLC now owns 24,112 shares of the medical research company's stock worth $1,355,000 after purchasing an additional 18,772 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Exact Sciences by 30.0% in the 4th quarter. Northern Trust Corp now owns 1,147,271 shares of the medical research company's stock valued at $64,465,000 after purchasing an additional 264,430 shares during the period. The Manufacturers Life Insurance Company lifted its position in shares of Exact Sciences by 1.1% in the fourth quarter. The Manufacturers Life Insurance Company now owns 138,086 shares of the medical research company's stock valued at $7,759,000 after buying an additional 1,494 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Exact Sciences during the 4th quarter valued at $12,663,000. Finally, Nebula Research & Development LLC acquired a new position in shares of Exact Sciences in the fourth quarter valued at $3,284,000. 88.82% of the stock is owned by institutional investors.

Exact Sciences Trading Up 0.2 %

Shares of EXAS stock traded up $0.08 during mid-day trading on Thursday, reaching $53.36. The company's stock had a trading volume of 404,535 shares, compared to its average volume of 2,646,660. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12-month low of $39.97 and a 12-month high of $72.83. The firm has a market capitalization of $10.07 billion, a PE ratio of -9.58 and a beta of 0.92. The company's 50 day simple moving average is $45.36 and its 200-day simple moving average is $53.07.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical research company reported ($0.21) EPS for the quarter, topping analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The firm had revenue of $706.79 million during the quarter, compared to the consensus estimate of $688.58 million. During the same period in the prior year, the business earned ($0.60) EPS. The firm's revenue was up 10.9% on a year-over-year basis. On average, research analysts predict that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Robert W. Baird increased their price target on shares of Exact Sciences from $69.00 to $72.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Benchmark reissued a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Piper Sandler dropped their price target on shares of Exact Sciences from $75.00 to $70.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Bank of America reduced their price objective on shares of Exact Sciences from $72.00 to $65.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Finally, Scotiabank upped their price objective on Exact Sciences from $70.00 to $73.00 and gave the stock a "sector outperform" rating in a research report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Exact Sciences has a consensus rating of "Moderate Buy" and an average price target of $70.90.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.